An observational study in Autism Spectrum Disorder and Autism Spectrum Disorder With Absence of Functional Language, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Recruiting at 1 site in Spain. Open to participants aged 16 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-06-27.
Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Autism Spectrum Disorder with a site in Spain — 7 open to participants now, 9 under way, 2 of them phase 3. Autism Spectrum Disorder · Spain.
Among the 32 studies in Autism Spectrum Disorder with a site in Spain, this one is one of 5 that started in 2024, is one of 5 observational ones, and was the 30th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →7 of the 32 studies in Autism Spectrum Disorder with a site in Spain are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Spain, United States, France and 7 more countries
Ages 5–17
Hospital General Universitario Gregorio Marañon · Sites in Spain, France
Ages 0–64
University of Vic - Central University of Catalonia · Sites in Spain
Ages 4–11 · Healthy volunteers
Stalicla SA · Sites in Spain, United States, Australia
Ages 12–65
Fundació Sant Joan de Déu · Sites in Spain
Ages 3–8
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 16 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 7
First in 2012; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 37 is below the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 102 across the 27 interventional studies, 135 across the 5 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 32 have an industry lead sponsor. The 10 most frequent:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the lead sponsor of 343 studies on the registry; 65 are open to participants now.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau has 2 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
3 of the studies in Autism Spectrum Disorder with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07655115Phase 3Hospital General Universitario Gregorio MarañonSingle Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th | 2026-12-31 |
| NCT06108583Fundació Sant Joan de DéuEvaluation of the Effect of a Psychological Program for Children With Autism Spectrum Disorder and Feeding Difficulties | 2026-12-31 |
| NCT05590715Stalicla SAInternational Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Autism Spectrum Disorder with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Currently, many autistic youths struggle to adapt to academic programs or the workforce, often turning to third-sector organizations such as specialized associations and foundations. This may be due to factors such as emotional dysregulation and executive dysfunction, which interfere with their psychosocial adaptation abilities, leading to anxiety and depression. These challenges have a neurobiological basis tied to the unique complexities of the autistic brain, which experiences emotional and cognitive overload and lacks attentional filters. To address this issue, the emotional and executive functioning of autistic youths at the Friends Foundation will be assessed through objective and subjective assessments.
This data collection will serve as a foundation for conceptualizing and co-creating a more realistic affective-cognitive remediation program, integrating user perspectives (conceptualization of interventions for systematic implementation). The program aims to improve the socio-occupational and emotional adaptation difficulties that often contribute to mental health challenges within this underserved population. It is important to highlight that many existing programs focus on cognitive training and social skills, neglecting strategies for adaptation and emotional regulation. This project will stand out for its inclusive design, featuring a representative sample of both sexes, overcoming the usual limitation of male-centered approaches.
The mixed or hybrid sequential study design (quantitative → qualitative → quantitative) includes three parts:
A) Assessment of socio-occupational, neuropsychological, and psychological variables to establish relationships between the degree of impairment and socio-occupational integration. Quantitative study.
B) Focus groups to determine the contents of the intervention program, which will be co-created as the Aut-CARE program. Qualitative study.
C) Pilot study of the Aut-CARE program to evaluate its format, content, feasibility, and acceptability.
Individuals aged 16 to 30 years with an ASD diagnosis, levels 1 and 2. The calculated sample size is 37 subjects for sub-study A; the minimum sample size for the focus groups (sub-study B) is 14; and a maximum of 10 participants for the pilot study (sub-study C).
Individuals (females and males) aged 16 to 30 years with an ASD diagnosis, levels 1 and 2
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There is no intervention
Difficulties in emotion regulation scale (DERS)
The DERS is a measure of emotional dysregulation. The raw scores range from 36 to 180. Higher scores mean more difficulties.
Time frame: 1 day
Battery of cognitive tests
A set of neuropsychological tests is administered: Trail Making Test-A, Trail Making Test-B, Digit Symbol Substitution Test, Digit Span, Letter and Numbers, and Phonetic Fluency (PMR). Scores will be t-transformed (mean=50, SD=10), so high scores mean better performance.
Time frame: 1 day
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Sep 2026, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau →